ArticleMethods in molecular biology (Clifton, N.J.)2026
Phage Display In Vivo: Protocols for Identifying Brain-Targeting Peptides in Mouse Models of Neurodegeneration.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vivo phage display is a versatile strategy for an unbiased identification of peptide ligands that selectively interact with molecular targets, in vitro, in cell, and in vivo, in living organisms. In a previous study, we validated this technology to identify a brain targeting peptide. Here, we detail the protocol for selection using phage display in vivo of peptide targeting the mouse brain, in health and disease. Given the need of alternative models to study degenerative disease, such as Alzheimer's disease, we elected the murine model of neuroinflammation and neurodegeneration as an example. This model utilizes the stereotaxic intracerebroventricular administration of streptozotocin (STZ) to induce neuroinflammation, an event that recapitulates key pathological hallmarks of Alzheimer's disease. Following the establishment of the disease model, a randomized phage display peptide library-a collection of billions of phages, each displaying a different peptide sequence on their surface-is administered intravenously into healthy and diseased mice. This allows selective interaction of individual phage with vascular, tissue-specific receptors under physiological or in a pathological condition with which a compromised blood-brain barrier may alter brain homeostasis. After systemic circulation, animals undergo perfusion and organs are harvested for phage recovery and amplification, followed by iterative rounds of biopanning to enrich for high-affinity ligands. This approach offers a robust platform for the discovery of novel diagnostic probes, therapeutic ligands, and molecular markers relevant to brain biology, in health, neuroinflammation and neurodegeneration. Most importantly, the adaptability of this technology enables its application across diverse murine models of human disease, thereby establishing an easy and systematic approach to facilitate the translation of laboratory discoveries into a wide spectrum of human diseases.
Indexed as
Identifiers
42681186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.